201 related articles for article (PubMed ID: 32424570)
1. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
Ayala-Aguilera CC; Valero T; Lorente-Macías Á; Baillache DJ; Croke S; Unciti-Broceta A
J Med Chem; 2022 Jan; 65(2):1047-1131. PubMed ID: 34624192
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Wu P; Nielsen TE; Clausen MH
Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
[TBL] [Abstract][Full Text] [Related]
4. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
[TBL] [Abstract][Full Text] [Related]
5. Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA-approved targeted small molecule oncology drugs.
Kotani N; Ito K
Clin Transl Sci; 2023 Aug; 16(8):1359-1368. PubMed ID: 37173825
[TBL] [Abstract][Full Text] [Related]
6. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
[TBL] [Abstract][Full Text] [Related]
7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
8. Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial.
Oda Y; Narukawa M
BMC Cancer; 2022 Mar; 22(1):277. PubMed ID: 35291959
[TBL] [Abstract][Full Text] [Related]
9. Early accelerated approval for highly targeted cancer drugs.
Chabner BA
N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
[No Abstract] [Full Text] [Related]
10. An appraisal of drug development timelines in the Era of precision oncology.
Jardim DL; Schwaederle M; Hong DS; Kurzrock R
Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the recommended phase 2 dose of molecular targeted agents.
Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
[TBL] [Abstract][Full Text] [Related]
14. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
[TBL] [Abstract][Full Text] [Related]
15. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
[TBL] [Abstract][Full Text] [Related]
16. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
17. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
Mittapalli RK; Yin D; Beaupre D; Palaparthy R
Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
[TBL] [Abstract][Full Text] [Related]
18. Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates.
Malek E; Saygin C; Ye R; Covut F; Kim BG; Welge J; Meropol NJ; De Lima M; Driscoll JJ
JCO Clin Cancer Inform; 2017 Nov; 1():1-14. PubMed ID: 30657399
[TBL] [Abstract][Full Text] [Related]
19. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
